Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 505 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Second CAR T-Cell Therapy for Lymphoma May 22, 2018 People with Intellectual Disability at Increased Risk of Cancer September 21, 2021 Best Friends and Owners of a Specialty Cheese Shop Battle Breast... June 11, 2021 Scientists Focus on Fusion Proteins in Childhood Cancers August 4, 2020 Load more HOT NEWS Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer... Exosomes May Help Tumors Evade Immune System
